Abstract
Phospho-MurNAc-pentapeptide translocase (MraY, translocase I) catalyses the first step of the lipid-linked cycle of reactions of bacterial peptidoglycan biosynthesis. MraY is the target for five families of nucleoside antibacterial natural products: the tunicamycins, the mureidomycins (also pacidamycins, napsamycins), the liposidomycins, the muraymycins, and the capuramycins. Recent structure-activity studies on these families have led to the identification of active pharmacophores, and insight into their mechanisms of action. This step of peptidoglycan biosynthesis is also the target for the bacteriolytic E protein from bacteriophage φX174, and for cyclic peptides of the amphomycin family which complex the undecaprenyl phosphate co-substrate. The mechanisms of enzyme inhibition by these agents are discussed, and the state of knowledge regarding the transmembrane structure, active site, and catalytic mechanism of MraY. The availability of high throughput assays and prospects of MraY as an antibacterial target are also discussed.
Keywords: Peptidoglycan biosynthesis, antibacterial agents, MraY, high-throughput screening
Infectious Disorders - Drug Targets
Title: Phospho-MurNAc-Pentapeptide Translocase (MraY) as a Target for Antibacterial Agents and Antibacterial Proteins
Volume: 6 Issue: 2
Author(s): Timothy D.H. Bugg, Adrian J. Lloyd and David I. Roper
Affiliation:
Keywords: Peptidoglycan biosynthesis, antibacterial agents, MraY, high-throughput screening
Abstract: Phospho-MurNAc-pentapeptide translocase (MraY, translocase I) catalyses the first step of the lipid-linked cycle of reactions of bacterial peptidoglycan biosynthesis. MraY is the target for five families of nucleoside antibacterial natural products: the tunicamycins, the mureidomycins (also pacidamycins, napsamycins), the liposidomycins, the muraymycins, and the capuramycins. Recent structure-activity studies on these families have led to the identification of active pharmacophores, and insight into their mechanisms of action. This step of peptidoglycan biosynthesis is also the target for the bacteriolytic E protein from bacteriophage φX174, and for cyclic peptides of the amphomycin family which complex the undecaprenyl phosphate co-substrate. The mechanisms of enzyme inhibition by these agents are discussed, and the state of knowledge regarding the transmembrane structure, active site, and catalytic mechanism of MraY. The availability of high throughput assays and prospects of MraY as an antibacterial target are also discussed.
Export Options
About this article
Cite this article as:
Bugg D.H. Timothy, Lloyd J. Adrian and Roper I. David, Phospho-MurNAc-Pentapeptide Translocase (MraY) as a Target for Antibacterial Agents and Antibacterial Proteins, Infectious Disorders - Drug Targets 2006; 6 (2) . https://dx.doi.org/10.2174/187152606784112128
DOI https://dx.doi.org/10.2174/187152606784112128 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Approaches to Target the Mycolic Acid Biosynthesis Pathway for the Development of Tuberculosis Therapeutics
Current Pharmaceutical Design Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Chemical Constituents of Plants from the Genus Valeriana
Mini-Reviews in Organic Chemistry 4-Aminoquinoline Based Molecular Hybrids as Antimalarials: An Overview
Current Topics in Medicinal Chemistry Editorial
Recent Patents on Inflammation & Allergy Drug Discovery Antimicrobial Evaluation of Some Arylsulfanylpyrazinecarboxylic Acid Derivatives
Medicinal Chemistry Recent Development and Application of Virtual Screening in Drug Discovery: An Overview
Current Pharmaceutical Design Management of Spondyloarthropathy in Asian Countries
Current Rheumatology Reviews The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Patent Selections:
Recent Patents on Anti-Infective Drug Discovery The Antibiotic Potential of Prokaryotic IMP Dehydrogenase Inhibitors
Current Medicinal Chemistry Antimycotic Drugs and their Mechanisms of Resistance to <i>Candida</i> Species
Current Drug Targets Prediction of Small Molecules Metabolic Pathways Based on Functional Group Composition
Protein & Peptide Letters Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease (COPD): Focus on Virus Induced Exacerbations
Current Pharmaceutical Design Long-Term Treatment With Raltegravir is Associated with Lower Triglycerides and Platelets Count in the Older HIV+ Population: Results from the Ral-Age Study
Current HIV Research Bioinformatics and Drug Discovery
Current Topics in Medicinal Chemistry The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy
Current Pharmaceutical Design Cytokines in Systemic Lupus Erythematosus
Current Molecular Medicine Monoaminergic Neurotransmission: The History of the Discovery of Antidepressants from 1950s Until Today
Current Pharmaceutical Design 4,6-diaryl Pyrimidones as Constrained Chalcone Analogues: Design, Synthesis and Evaluation as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry